nach oben

best practice onkologie

Erschienen in:

23.03.2021 | Ovarialkarzinom | Hot-Topic

Hot Topic – Operative Strategien beim Ovarialkarzinom

verfasst von: Dr. A. M. Dückelmann, Prof. Dr. Dr. J. Sehouli

Erschienen in: best practice onkologie | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Debulking-Operation mit anschließender platin- und taxanbasierten adjuvanten Therapie gilt als Therapiestandard für das fortgeschrittene Ovarialkarzinom. Aufgrund später Symptome wird das Ovarialkarzinom zumeist im fortgeschrittenen Stadium diagnostiziert. Patientinnen mit optimaler Tumorresektion (makroskopische Tumorfreiheit) haben die beste Prognose, dies trifft sowohl in der Primär- als auch in der Rezidivsituation zu. Bislang gibt es keine Methode, um die Möglichkeit einer vollständigen Tumorentfernung vorherzusagen. Das neoadjuvante Therapiekonzept mit anschließender Intervall-Op. kommt für die Patientin im schlechten Zustand infrage, wenn eine kurzfristige Verbesserung unwahrscheinlich erscheint bzw. wenn eine Tumorreduktion < 1 cm nicht möglich ist. Eine primäre Chemotherapie sollte bei Patientinnen mit unresezierbarer Tumorlast erfolgen. Bei platinsensitivem Rezidiv ist die Möglichkeit einer Rezidiv-Op. zu prüfen und ggf. anzubieten. Alle Ovarialkarzinompatientinnen sollten an einem Gyn-Onko-Zentrum von einem gynäkologischen Onkologen behandelt werden.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E586PubMed

Oberaigner W, Minicozzi P, Bielska-Lasota M, Allemani C, de Angelis R, Mangone L et al (2012) Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol 51(4):441–453PubMed

Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G et al (2016) Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer 122(12):1844–1852PubMed

Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A et al (2009) Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10(4):327–340PubMed

Foley OW, Rauh-Hain JA, del Carmen MG (2013) Recurrent epithelial ovarian cancer: an update on treatment. Oncology 27(4):288–94, 98PubMed

Griffiths CT, Fuller AF (1978) Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am 58(1):131–142PubMed

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259PubMed

Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21(2):289–295PubMed

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2020) S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Langversion 4.0

10.

Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG et al (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 26(1):83–89PubMed

11.

Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R et al (2011) Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 121(3):615–619PubMed

12.

Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J et al (2011) 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21(4):750–755PubMed

13.

du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115(6):1234–1244PubMed

14.

Chang SJ, Hodeib M, Chang J, Bristow RE (2013) Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 130(3):493–498PubMed

15.

Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA et al (2015) Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol 33(8):937–943PubMedPubMedCentral

16.

Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D et al (2017) European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. Int J Gynecol Cancer 27(7):1534–1542PubMed

17.

Muallem MZ, Sehouli J, Miranda A, Richter R, Muallem J (2020) Total retroperitoneal en bloc resection of multivisceral-peritoneal packet (TROMP operation): a novel surgical technique for advanced ovarian cancer. Int J Gynecol Cancer 30(5):648–653PubMed

18.

Mercado C, Zingmond D, Karlan BY, Sekaris E, Gross J, Maggard-Gibbons M et al (2010) Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecol Oncol 117(1):18–22PubMed

19.

Prat J, Oncology FCoG (2014) Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124(1):1–5PubMed

20.

Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D et al (2016) European Society of Gynaecologic oncology quality indicators for advanced ovarian cancer surgery. Int J Gynecol Cancer 26(7):1354–1363PubMed

21.

Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I et al (2013) The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma—analysis of patient data in the prospective OVCAD study. Gynecol Oncol 131(1):15–20PubMed

22.

Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G et al (2016) Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 17(11):1579–1589PubMed

23.

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379(26):2495–2505PubMed

24.

González-Martín APB, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381:2391–2402PubMed

25.

Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381(25):2416–2428PubMed

26.

Glajzer J, Grabowski JP, Sehouli J, Pfisterer J (2020) Recurrent treatment in ovarian cancer patients: what are the best regimens and the order they should be given? Curr Treat Options Oncol 21(6):49PubMed

27.

Oskay-Ozcelik G, Alavi S, Richter R, Keller M, Chekerov R, Cecere SC et al (2018) Expression III: patients’ expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. Ann Oncol 29(4):910–916PubMed

28.

Rohr I, Alavi S, Richter R, Keller M, Chekerov R, Oskay-Ozcelik G et al (2020) Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV). Int J Gynecol Cancer 30(4):509–514PubMed

29.

May T, Comeau R, Sun P, Kotsopoulos J, Narod SA, Rosen B et al (2017) A comparison of survival outcomes in advanced serous ovarian cancer patients treated with primary debulking surgery versus neoadjuvant chemotherapy. Int J Gynecol Cancer 27(4):668–674PubMed

30.

Gomez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL et al (2015) Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol 137(3):553–558PubMedPubMedCentral

31.

Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL et al (2016) Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 34(28):3460–3473PubMed

32.

Nasser S, Lazaridis A, Evangelou M, Jones B, Nixon K, Kyrgiou M et al (2016) Correlation of pre-operative CT findings with surgical & histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: a retrospective evaluation. Gynecol Oncol 143(2):264–269PubMed

33.

Michielsen K, Dresen R, Vanslembrouck R, De Keyzer F, Amant F, Mussen E et al (2017) Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. Eur J Cancer 83:88–98PubMed

34.

Fischerova D, Zikan M, Semeradova I, Slama J, Kocian R, Dundr P et al (2017) Ultrasound in preoperative assessment of pelvic and abdominal spread in patients with ovarian cancer: a prospective study. Ultrasound Obstet Gynecol 49(2):263–274PubMed

35.

Petrillo M, Vizzielli G, Fanfani F, Gallotta V, Cosentino F, Chiantera V et al (2015) Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept. Gynecol Oncol 139(1):5–9PubMed

36.

Greggi S, Falcone F, Scaffa C, du Bois A, Samartzis EPP, Pujade-Lauraine E et al (2020) Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey. Int J Gynecol Cancer 30(6):819–824PubMed

37.

Vizzielli G, Costantini B, Tortorella L, Pitruzzella I, Gallotta V, Fanfani F et al (2016) A laparoscopic risk-adjusted model to predict major complications after primary debulking surgery in ovarian cancer: a single-institution assessment. Gynecol Oncol 142(1):19–24PubMed

38.

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q et al (2017) A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecol Oncol 145(1):27–31PubMedPubMedCentral

39.

Schneider S, Armbrust R, Spies C, du Bois A, Sehouli J (2020) Prehabilitation programs and ERAS protocols in gynecological oncology: a comprehensive review. Arch Gynecol Obstet 301(2):315–326PubMed

40.

Sehouli J, Heise K, Richter R, Woopen H, Anders L, Inci MG (2020) Preoperative quality of life as prediction for severe postoperative complications in gynecological cancer surgery: results of a prospective study. Arch Gynecol Obstet. https://doi.org/10.1007/s00404-020-05847-1CrossRefPubMedPubMedCentral

41.

Kumar A, Janco JM, Mariani A, Bakkum-Gamez JN, Langstraat CL, Weaver AL et al (2016) Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. Gynecol Oncol 140(1):15–21PubMed

42.

Inci MG, Richter R, Woopen H, Rasch J, Heise K, Anders L et al (2020) Role of predictive markers for severe postoperative complications in gynecological cancer surgery: a prospective study (RISC-Gyn Trial). Int J Gynecol Cancer 30(12):1975–1982PubMed

43.

Inci MG, Anders L, Heise K, Richter R, Woopen H, Sehouli J (2020) Can Fried Frailty Score predict postoperative morbidity and mortality in gynecologic cancer surgery? Results of a prospective study. J Geriatr Oncol. https://doi.org/10.1016/j.jgo.2020.09.029CrossRefPubMed

44.

van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G et al (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332(10):629–634PubMed

45.

Plett H, Filippova OT, Garbi A, Kommoss S, Rosendahl M, Langstraat C et al (2020) Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. Gynecol Oncol 159(2):434–441PubMedPubMedCentral

46.

Babayeva A, Braicu EI, Grabowski JP, Gasimli K, Richter R, Muallem MZ et al (2018) Clinical outcome after completion surgery in patients with ovarian cancer: the Charite experience. Int J Gynecol Cancer 28(8):1491–1497PubMed

47.

Onda T, Satoh T, Ogawa G, Saito T, Kasamatsu T, Nakanishi T et al (2020) Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer 130:114–125PubMed

48.

Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T et al (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386(9990):249–257PubMed

49.

Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953PubMed

50.

Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM et al (2012) An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 124(1):10–14PubMed

51.

Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS et al (2013) Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecol Oncol 131(2):437–444PubMed

52.

Leary A, Cowan R, Chi D, Kehoe S, Nankivell M (2016) Primary surgery or neoadjuvant chemotherapy in advanced ovarian cancer: the debate continues. Am Soc Clin Oncol Educ Book 35:153–162PubMed

53.

Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V et al (2020) Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer 30(11):1657–1664PubMed

54.

Fagotti A, Vizzielli G, De Iaco P, Surico D, Buda A, Mandato VD et al (2013) A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol 209(5):462e1–462e11

55.

Reuss A, du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G et al (2019) TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Int J Gynecol Cancer 29(8):1327–1331PubMed

56.

Fotopoulou C, Sehouli J, Aletti G, Harter P, Mahner S, Querleu D et al (2017) Value of neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer: a European perspective. J Clin Oncol 35(6):587–590PubMed

57.

Jiang R, Zhu J, Kim JW, Liu J, Kato K, Kim HS et al (2020) Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept. J Gynecol Oncol 31(5):e86PubMedPubMedCentral

58.

Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C et al (2019) A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 380(9):822–832PubMed

59.

Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage WG, McNeish I et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer 29:728–760

60.

Hasenburg A, Sehouli J, Lampe B, Reuss A, Schmalfeld B, Belau AK et al (2020) LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial. Int J Gynecol Cancer 30(10):1548–1553PubMed

61.

Markman M (2003) Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4(5):277–283PubMed

62.

Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E et al (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22(5):1570–1575PubMed

63.

Lim MCCS‑J, Yoo HJ, Nam B‑H, Bristow R, Park S‑Y (2017) Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol 35(15_suppl):5520–5520. https://doi.org/10.1200/JCO.2017.35.15_suppl.5520CrossRef

64.

Fotopoulou C, Sehouli J, Mahner S, Harter P, Van Nieuwenhuysen E, Gonzalez-Martin A et al (2018) HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? Ann Oncol 29(8):1610–1613PubMed

65.

van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230–240PubMed

66.

Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D et al (2020) Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC‑2, a phase III randomized clinical trial. Int J Gynecol Cancer 30(6):888–892PubMedPubMedCentral

67.

Vergote I, Chiva L, du Bois A (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(14):1362–1363PubMed

68.

Bentivegna E, Gouy S, Maulard A, Pautier P, Leary A, Colombo N et al (2016) Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues. Ann Oncol 27(11):1994–2004PubMed

69.

Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC (2017) Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol 35(10):1103–1111PubMedPubMedCentral

70.

Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC et al (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376(9747):1155–1163PubMed

71.

Salani R, Khanna N, Frimer M, Bristow RE, Chen LM (2017) An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 146(1):3–10PubMed

72.

Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S et al (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13(12):1702–1710PubMed

73.

Sehouli J, Grabowski JP (2019) Surgery in recurrent ovarian cancer. Cancer 125(Suppl 24):4598–4601PubMed

74.

Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM et al (2017) Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol 28(4):727–732PubMed

75.

Muallem MZ, Gasimli K, Richter R, Almuheimid J, Nasser S, Braicu EI et al (2015) AGO score as a predictor of surgical outcome at secondary cytoreduction in patients with ovarian cancer. Anticancer Res 35(6):3423–3429PubMed

76.

Du Bois ASJ, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Jensen PT, Selle F, Guyon F, Pomel C, Lecuru F, Zang R, Avall-Lundqvist E, Kim J‑W, Ponce J, Raspagliesi F, Ghaem-Maghami S, Reinthaller A, Harter P (2020) Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20. J Clin Oncol. https://doi.org/10.1200/JCO.2020.38.15_suppl.6000CrossRef

77.

Zang RZJ, Shi T, Liu J, Tu D, Yin S, Jiang R, Zhang P, Jia H, Luan Y, Zhang Y, Chen X, Huang X, Tian W, Gao W, Feng Y, Yang H, Cheng X, Cai Y (2020) A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2. J Clin Oncol. https://doi.org/10.1200/JCO.2020.38.15_suppl.6001CrossRef

78.

Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK et al (2019) Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med 381(20):1929–1939PubMedPubMedCentral

79.

Vergote I, du Bois A, Amant F, Heitz F, Leunen K, Harter P (2013) Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree? Gynecol Oncol 128(1):6–11PubMed

80.

Riester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E et al (2014) Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst 106(5):dju048. https://doi.org/10.1093/jnci/dju048CrossRefPubMedPubMedCentral

81.

Braicu EKH, Dreher F, Darb-Esfahani S, Taube E, Chekerov R, Kessler T, Muallem M, Wierling C, Denkert C, Lammert H, Hummel M, Sehouli J (2018) Gene expression profiling using Nanostring technology to predict surgical outcome in advanced primary high grade serous ovarian cancer (HGSOC) patients (pts). Study of the Tumor Bank Ovarian Cancer (TOC). J Clin Oncol 36:abstr. 5569

82.

Dückelmann AM, Sehouli J (2018) Optimales OP-Timing beim Ovarialkarzinom. J Onkol 2018(9):55–58

Titel: Hot Topic – Operative Strategien beim Ovarialkarzinom
verfasst von: Dr. A. M. Dückelmann
Prof. Dr. Dr. J. Sehouli
Publikationsdatum: 23.03.2021
Verlag: Springer Medizin
Schlagwörter: Ovarialkarzinom
Zytostatische Therapie
Ovarialkarzinom
Erschienen in: best practice onkologie / Ausgabe 4/2021
Print ISSN: 0946-4565
Elektronische ISSN: 1862-8559
DOI: https://doi.org/10.1007/s11654-021-00303-1

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Hot Topic – Operative Strategien beim Ovarialkarzinom

Zusammenfassung

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

CME: Künstliche Intelligenz und maschinelles Lernen in der onkologischen Bildgebung

Editorial

Hot Topic – Zervixkarzinom: kontra minimal-invasive Operation

Erhöhtes Brustkrebs-Rückfallrisiko durch Rheuma-Biologika?

Moderne Molekularpathologie eng verzahnt mit klassischer Histologie

onko-aktuell

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Update Onkologie